ORIC Pharmaceuticals reports on June 18 carrying one of the heaviest short positions in its peer group — and a stock that has just broken higher despite it.
Short interest is the defining feature of this setup. Bears have built a position equal to 22.4% of the free float, a level ORTEX classifies as high, and that position has grown roughly 8% over the past month. Days to cover runs at 17, meaning shorts face a multi-week exit if the print triggers a sustained rally. The ORTEX short score of 72.6 confirms the elevated pressure, though it has eased slightly from a reading near 74.6 earlier this month. Notably, the borrow market tells a calmer story: availability runs at nearly 296% — meaning nearly three shares are available to lend for every one already borrowed — and borrowing costs remain subdued at 0.61%. That looseness suggests the short thesis is conviction-driven rather than a product of a crowded, expensive borrow.
The bull-bear divide on ORIC is a familiar clinical-stage binary. Bulls point to upcoming dose-optimisation data for ORIC-944 and enozertinib pipeline updates as potential re-rating catalysts, and the Street consensus remains constructive — Goldman Sachs upgraded to Buy in May with a $15 target, and the mean analyst target of around $20 implies roughly 140% upside from the current $8.40. Bears counter with zero product revenue, a pipeline still entirely in the clinical stage, and safety questions around rinzimetostat given the withdrawal of a related compound from another company. Several analysts have trimmed targets in recent months even while holding positive ratings, a signal that conviction exists but valuation tolerance is narrowing.
The price action heading into the print is worth noting. ORIC has rallied 11.6% over the past week and 3.1% over the past month to close at $8.40, outperforming several correlated peers. That move has come against a backdrop of persistently heavy short interest — which means short sellers have not yet blinked. T. Rowe Price added over two million shares through May, a material addition, while Pfizer Venture Investments trimmed by roughly 1.9 million, leaving the institutional picture mixed. The two most recent earnings prints both produced negative one-day and five-day reactions, with five-day losses averaging around 8%.
The June 18 print will test whether the upcoming clinical catalysts are credible enough to force a rethink from a short base that has grown steadily for a month, or whether the stock's recent bounce simply gives bears a better entry.
See the live data behind this article on ORTEX.
Open ORIC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
